Wealth Enhancement Advisory Services’s Ionis Pharmaceuticals IONS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$262K Buy
6,058
+664
+12% +$37.7K ﹤0.01% 3487
2026
Q2
$314K Buy
5,394
+1,269
+31% +$95.5K ﹤0.01% 3160
2026
Q1
$309K Sell
4,125
-4,131
-50% -$326K ﹤0.01% 2743
2025
Q4
$673K Buy
8,256
+817
+11% +$61.5K ﹤0.01% 2248
2025
Q3
$513K Sell
7,439
-476
-6% -$23.2K ﹤0.01% 2345
2025
Q2
$340K Buy
+7,915
New +$259K ﹤0.01% 2542
2024
Q3
– Sell
-4,508
Closed -$215K – 2861
2024
Q2
$215K Buy
+4,508
New +$185K ﹤0.01% 2242

Other funds holding IONS

Wealth Enhancement Advisory Services's IONS Position: Q3 2026 in Review

Wealth Enhancement Advisory Services increased its Ionis Pharmaceuticals (IONS) stake by 12% in Q3 2026, buying an estimated $37.7K and bringing the position to 6,058 shares worth $262K. The position accounts for ﹤0.01% of the portfolio, ranked #3487.

Wealth Enhancement Advisory Services first reported a position in IONS in Q2 2024 and has held it in 7 quarters since. The position peaked at $673K in Q4 2025. 465 funds tracked by Wall St. Rank hold IONS as of Q3 2026.

  • Wealth Enhancement Advisory Services held 6,058 shares of Ionis Pharmaceuticals worth $262K as of Q3 2026.
  • Wealth Enhancement Advisory Services bought 664 Ionis Pharmaceuticals shares in Q3 2026, an estimated $37.7K.
  • Ionis Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3487 holding.
  • Wealth Enhancement Advisory Services first reported a position in Ionis Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
  • Wealth Enhancement Advisory Services's Ionis Pharmaceuticals position peaked at $673K in Q4 2025.
  • 465 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.